Drugs for Estrogen-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 147)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 4 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
2 |
|
Lactitol |
Approved, Investigational |
Phase 4 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
3 |
|
Epirubicin |
Approved |
Phase 4 |
|
56420-45-2 |
41867 |
Synonyms:
4' Epi adriamycin
4' Epi doxorubicin
4' Epi DXR
4' Epiadriamycin
4' Epidoxorubicin
4'-Epiadriamycin
4'-Epi-adriamycin
4'-Epidoxorubicin
4'-Epi-doxorubicin
4'-Epi-DXR
Cell pharm brand OF epirubicin
Ellence
EPI cell
Epiadriamycin
EPIcell
EPI-cell
Epidoxorubicin
Epi-Dx
Epilem
Epirubicin
Epirubicin hydrochloride
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
|
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin
Farmorubicina
Farmorubicine
Hydrochloride, epirubicin
IMI 28
IMI28
IMI-28
Kenfarma brand OF epirubicin hydrochloride
Lemery brand OF epirubicin hydrochloride
NSC-256942
Pfizer brand OF epirubicin hydrochloride
Pharmorubicin
Pharmorubicin Pfs
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
|
|
4 |
|
Docetaxel |
Approved, Investigational |
Phase 4 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
5 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
6 |
|
Immunosuppressive Agents |
|
Phase 4 |
|
|
|
7 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
8 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
9 |
|
Alkylating Agents |
|
Phase 4 |
|
|
|
10 |
|
Antineoplastic Agents, Alkylating |
|
Phase 4 |
|
|
|
11 |
|
Antimitotic Agents |
|
Phase 4 |
|
|
|
12 |
|
Tubulin Modulators |
|
Phase 4 |
|
|
|
13 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
14 |
|
Letrozole |
Approved, Investigational |
Phase 3 |
|
112809-51-5 |
3902 |
Synonyms:
4,4'-(1H-1,2,4-Triazol-1-yl-methylene)-bis(benzonitrile)
CGS-20267
FEM345
Femara
Fémara
|
Femara®
Letrozol
LETROZOLE
Novartis brand OF letrozole
|
|
15 |
|
Sodium citrate |
Approved, Investigational |
Phase 3 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
16 |
|
Capecitabine |
Approved, Investigational |
Phase 2, Phase 3 |
|
154361-50-9 |
60953 |
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
CAPECITABINE
Capécitabine
Capecitabinum
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
|
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
R340
RO-091978000
RO-09-1978000
RO-09-1978-000
Ro-09-1978-000|Ro-091978000|Xeloda®
Xeloda
|
|
17 |
|
Exemestane |
Approved, Investigational |
Phase 2, Phase 3 |
|
107868-30-4 |
60198 |
Synonyms:
6-Methyleneandrosta-1,4-diene-3,17-dione
Aromasil
Aromasin
Aromasin®|FCE-24304
Aromasine
Examestane
Exemestance
|
EXEMESTANE
Exemestano
Exemestano [INN-Spanish]
Exemestanum
Exemestanum [INN-Latin]
FCE-24304
PNU-155971
|
|
18 |
|
Anastrozole |
Approved, Investigational |
Phase 2, Phase 3 |
|
120511-73-1 |
2187 |
Synonyms:
2,2'-(5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
a,a,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Anastrazole
Anastrole
Anastrozol
ANASTROZOLE
Arimidex
Arimidex®
Astra brand OF anastrozole
|
AstraZeneca brand OF anastrozole
ICI D1033
ICI-D1033
NASTROSA
ZD1033
ZD-1033
Zeneca brand OF anastrozole
Zeneca ZD 1033
Α,α,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
|
|
19 |
|
Tamoxifen |
Approved |
Phase 2, Phase 3 |
|
10540-29-1, 54965-24-1 |
2733526 |
Synonyms:
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
1-Para-b-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-Î’-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Apo-tamox
Citofen
Citrate, tamoxifen
Crisafeno
Diemon
EMBLON
FENTAMOX 10
FENTAMOX 20
Gen-tamoxifen
I.C.I.46474 CITRATE
ICI-46474
ICI-46474|Nolvadex®|Soltamox®
ICI-47699
Istubol
KENTADEX
KESSAR
KESSAR 10
KESSAR 20
Noltam
Nolvadex
NOLVADEX D
NOLVADEX FTE
Nolvadex-D
Nourytam
|
Novaldex
Novo-Tamoxifen
OESTRIFEN-10
OESTRIFEN-20
OESTRIFEN-40
Oncomox
PMS-Tamoxifen
Retaxim
Savient brand OF tamoxifen citrate
Soltamox
Tamizam
Tamofen
Tamone
Tamoplex
Tamoxasta
Tamoxen
TAMOXIFEN
Tamoxifen citrate
Tamoxifene
TAMOXIFÈNE
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tomaxithen
trans-Tamoxifen
Valodex
ZD6157
Zemide
Zitazonium
ZYNOPLEX
|
|
20 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
21 |
|
Tryptophan |
Approved, Nutraceutical, Withdrawn |
Phase 3 |
|
73-22-3 |
6305 |
Synonyms:
(-)-Tryptophan
(2S)-2-Amino-3-(1H-indol-3-yl)propanoate
(2S)-2-Amino-3-(1H-indol-3-yl)propanoic acid
(L)-Tryptophan
(S)-1H-Indole-3-alanine
(S)-2-AMINO-3-(1H-INDOL-3-YL)PROPANOIC ACID
(S)-2-Amino-3-(3-indolyl)propionic acid
(S)-a-Amino-1H-indole-3-propanoate
(S)-a-Amino-1H-indole-3-propanoic acid
(S)-a-Amino-b-(3-indolyl)-propionate
(S)-a-Amino-b-(3-indolyl)-propionic acid
(S)-a-Amino-b-indolepropionate
(S)-a-Amino-b-indolepropionic acid
(S)-a-Aminoindole-3-propionate
(S)-a-Aminoindole-3-propionic acid
(S)-alpha-Amino-1H-indole-3-propanoate
(S)-alpha-Amino-1H-indole-3-propanoic acid
(S)-alpha-Amino-beta-(3-indolyl)-propionate
(S)-alpha-Amino-beta-(3-indolyl)-propionic acid
(S)-alpha-Amino-beta-indolepropionate
(S)-alpha-Amino-beta-indolepropionic acid
(S)-alpha-Aminoindole-3-propionate
(S)-alpha-Aminoindole-3-propionic acid
(S)-Tryptophan
(S)-Α-amino-1H-indole-3-propanoate
(S)-Α-amino-1H-indole-3-propanoic acid
(S)-Α-amino-β-(3-indolyl)-propionate
(S)-Α-amino-β-(3-indolyl)-propionic acid
1beta-3-Indolylalanine
1-beta-3-Indolylalanine
1H-Indole-3-alanine
2-Amino-3-indolylpropanoate
2-Amino-3-indolylpropanoic acid
3-(1H-indol-3-yl)-L-Alanine
3-indol-3-Ylalanine
Alpha'-amino-3-indolepropionic acid
alpha-Amino-beta-(3-indolyl)-propionic acid
alpha-Aminoindole-3-propionic acid
Alti-Tryptophan
Ardeydorm
Ardeypharm brand OF tryptophan
Ardeytropin
Esparma brand OF tryptophan
GPPE PDR SACH
H-TRP-OH
ICN brand OF tryptophan
Indole-3-alanine
|
Kalma
Kalma brand OF tryptophan
L Tryptophan
L Tryptophan ratiopharm
L-(-)-Tryptophan
L(-)-TRYPTOPHAN
L-(−)-TRYPTOPHAN
l-a-Aminoindole-3-propionic acid
L-alpha-Amino-3-indolepropionic acid
L-alpha-Aminoindole-3-propionic acid
L-b-3-Indolylalanine
L-beta-3-Indolylalanine
Levotryptophan
Lopac-T-0254
L-TRP
L-Tryptofan
L-TRYPTOPHAN
L-Tryptophane
L-Tryptophan-ratiopharm
Lyphan
L-Î’-3-indolylalanine
Merck brand OF tryptophan
Naturruhe
Niddapharm brand OF tryptophan
NSC-13119
Optimax
OPTIMAX WV
Pacitron
Pharmascience brand OF tryptophan
PMS Tryptophan
PMS-Tryptophan
Ratio tryptophan
Ratiopharm brand OF tryptophan
Ratio-tryptophan
Sedanoct
Triptofano
Trofan
Trp
Tryptacin
Tryptan
Tryptophan
Tryptophan metabolism alterations
TRYPTOPHAN, L-
Tryptophane
Tryptophanum
Upsher-smith brand OF tryptophan
W
|
|
22 |
|
Citrate |
|
Phase 3 |
|
|
|
23 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
24 |
|
Antidepressive Agents |
|
Phase 3 |
|
|
|
25 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2, Phase 3 |
|
|
|
26 |
|
Estrogen Receptor Modulators |
|
Phase 2, Phase 3 |
|
|
|
27 |
|
Selective Estrogen Receptor Modulators |
|
Phase 2, Phase 3 |
|
|
|
28 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239 |
Synonyms:
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 43-9006|BAY-439006|Nexavar®
BAY-43-9006
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
|
Nexavar
SORAFENIB
Sorafénib
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
Sorafenibum
|
|
29 |
|
Metformin |
Approved |
Phase 2 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
30 |
|
Simvastatin |
Approved |
Phase 2 |
|
79902-63-9 |
54454 |
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8AR)-8-{2-[(2R,4R)-4-HYDROXY-6-OXOOXAN-2-YL]ETHYL}-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2,2-DIMETHYLBUTANOATE
2,2-Dimethylbutyrate, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
C10AA01
Cholestat
Coledis
Colemin
Corolin
Denan
Eucor
FLOLIPID
Kolestevan
Labistatin
LACERSA
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
Medipo
MK-0733
MK-733
MK-733|Zocor®
Modutrol
Nivelipol
Nor-vastina
Pantok
Pepstatin
RANZOLONT
|
Rechol
Rendapid
Simcor
Simovil
SIMVADOR
SIMVASTATIN
Simvastatin [Usan:Ban:Inn]
SIMVASTATIN HYDROXY ACID
Simvastatin lactone
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
SIV691
Sivastin
Statin
Synvinolin
Valemia
Vasotenal
Velostatin
Vytorin
Zocor
ZOCOR HEART-PRO
Zocord
|
|
31 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
32 |
|
Gefitinib |
Approved, Investigational |
Phase 2 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
33 |
|
Busulfan |
Approved, Investigational |
Phase 2 |
|
55-98-1 |
2478 |
Synonyms:
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Dimesyloxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulphonoxybutane
Bisulfex
Bisulphex
BUSILVEX
BUSULFAN
Busulfan glaxosmithkline brand
Busulfan orphan brand
Busulfan wellcome
Busulfan wellcome brand
Busulfano
Busulfanum
Busulfex
BUSULFEX IV
Busulphan
Busulphane
Busulphano
Busulphanum
Butanedioldimethanesulfonate
Buzulfan
Citosulfan
Glaxo wellcome brand OF busulfan
GlaxoSmithKline brand OF busulfan
Glyzophrol
Leucosulfan
|
Leucosulphan
Mablin
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
Myeleukon
Myeloleukon
Myelosan
Mylecytan
Myleran
Myléran
Myleran Tablets
N-Butane-1,3-di(methylsulfonate)
NCI-C01592
NSC-750
Orphan brand OF busulfan
Sulfabutin
Sulphabutin
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene dimethane sulfonate
Tetramethylenester kyseliny methansulfonove
Wellcome brand OF busulfan
Wellcome, busulfan
|
|
34 |
|
Melphalan |
Approved |
Phase 2 |
|
148-82-3 |
4053 460612 |
Synonyms:
2-Amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate
2-Amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoate
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-(Bis(2-chloroethyl)amino)phenylalanine
AIKERAN
ALANINE NITROGEN MUSTARD
Alkeran
CB-3025
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Levofalan
L-PAM
L-Phenylalanine mustard
L-PHENYLALANINE MUSTARD (L-PAM)
L-SARCOLYSIN
L-Sarcolysine
L-Sarkolysin
Medphalan
MELFALAN
Melfalano
Melphalan
|
Melphalanum
Mephalan
Merphalan
MLP673
Mustard, phenylalanine
NCI-C04853
NSC-241286
NSC-8806
p-Bis(b-chloroethyl)aminophenylalanine
p-Bis(beta-chloroethyl)aminophenylalanine
p-Bis(β-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
p-L-Sarcolysin
p-N,N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
Sarcolysin
Sarcolysine
Sarkolysin
SK 15673
SK-15673
|
|
35 |
|
Aldesleukin |
Approved |
Phase 2 |
|
110942-02-4 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Aldesleukin
Aldesleukina
IL-2
ILT101
ILT-101
Interleukin-2 aldesleukin
|
INTERLEUKIN-2 PRECURSOR
Interleukin-2(2-133),125-ser
Recombinant human interleukin-2
Recombinant interleukin-2 human
T-CELL GROWTH FACTOR
TCGF
|
|
36 |
|
Thiotepa |
Approved, Investigational |
Phase 2 |
|
52-24-4 |
5453 |
Synonyms:
Girostan
NSC-6396
Rethio
Tepadina
Tepadina®|Thioplex®
Tespa
Tespamin
Thio tepa
|
Thiophosphamide
Thioplex
Thio-tepa
THIOTEPA
THIOTEPA 或 THIOTEPA
Triethylenethiophosphoramide
Tris(1-aziridinyl)phosphine sulfide
|
|
37 |
|
Sargramostim |
Approved, Investigational |
Phase 2 |
|
123774-72-1 |
|
Synonyms:
B1 61.012
B1-61012
LEUKINE
RECOMBINANT GM-CSF
Recombinant human granulocyte-macrophage colony stimulating factor
|
rGM-CSF
RHU GM-CSF
RHU-GM-CSF
SARGRAMOSTIM
|
|
38 |
|
Cisplatin |
Approved |
Phase 2 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
39 |
|
Zoledronic acid |
Approved |
Phase 2 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
ácido zoledrónico
ACLASTA
Aclasta®|CGP-42446|CGP-42446A|Reclast®|zoledronate|Zometa®
ANHYDROUS ZOLEDRONIC ACID
CGP-42446
CGP-42446A
Novartis brand OF zoledronic acid
|
Reclast
ZERLINDA
ZOL
ZOL446
ZOLEDRONATE
Zoledronic acid
Zoledronic acid anhydrous
ZOLEDRONIC ACID HYDRATE
ZOLEDRONIC ACID MONOHYDRATE
ZOLEDRONIC ACID, ANHYDROUS
Zometa
Zometa Concentrate
|
|
40 |
|
Dasatinib |
Approved, Investigational |
Phase 2 |
|
302962-49-8 |
3062316 |
Synonyms:
(18F)-N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Anh. dasatinib
Anhydrous dasatinib
BMS 345825
BMS 345825|BMS 354825|BMS 35482513|Sprycel®
BMS 354825
BMS 35482513
BMS Dasatinib
BMS-354825
BMS-354825 HYDRATE
BMS-354825-03
|
DASATINIB
Dasatinib (anh.)
dasatinib (anhydrous)
DASATINIB ANHYDROUS
DASATINIB HYDRATE
DASATINIB MONOHYDRATE
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel
|
|
41 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
42 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 2 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
43 |
|
Caffeine |
Approved |
Phase 2 |
|
58-08-2 |
2519 |
Synonyms:
1,3,7-TRIMETHYL-2,3,6,7-TETRAHYDRO-1H-PURINE-2,6-DIONE
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-TRIMETHYLPURINE-2,6-QUINONE
1,3,7-Trimethylxanthine
137X
1-Methyltheobromine
1-Methyl-theobromine
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
7-Methyl theophylline
7-Methyltheophylline
Alert-Pep
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anoquan
Berlin-chemie brand OF caffeine
Bristol-myers squibb brand OF caffeine
Cafamil
CAFCIT
Cafecon
Cafeina
Cafeína
Cafeine
Caféine
Cafergot
Caffedrine
Caffedrine Caplets
Caffein
Caffeine
CAFFEINE MELTING POINT STANDARD
Caffeine Pure
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeinum
Caffine
Cafipel
CFF
Coffein
COFFEINE
Coffeinum
Coffeinum N
Coffeinum purrum
Compound 65
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
Durvitan
Eldiatric C
Enerjets
Ercatab
Esgic
Esgic-Plus
FEMA NO. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline brand OF caffeine
Guaranine
Hycomine
Invagesic
|
Invagesic Forte
Keep Alert
Kofein
Koffein
Lanorinal
Mateina
Mateína
Maximum Strength Snapback Stimulant Powders
Medigesic Plus
Merck dura brand OF caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Migergot
Miudol
Monohydrate caffeine
Monomethyl Derivative of Theophylline
Natural Caffeinum
Nix Nap
No doz
Nodaca
No-Doz
NODOZ
NODOZ CAPLETS AND CHEWABLE TABLETS
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
NSC-5036
Organex
Orphengesic
Orphengesic Forte
Passauer brand OF caffeine
Pep-Back
Percoffedrinol N
Percutaféine
Peyona®
Phensal
Pierre fabre brand OF caffeine
PRO-PLUS
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick pep
Quick-pep
QuickPep
Refresh'n
Republic drug brand OF caffeine
Respia
Seid brand OF caffeine
SK 65 Compound
Stim
Synalgos-Dc
Teina
Teína
Thein
Theine
Theobromine ME
Theophylline ME
Thompson brand 1 OF caffeine
Thompson brand 2 OF caffeine
Triad
Ultra Pep-Back
Vivarin
Wake-Up
Wigraine
YEAST-VITE
ZANTHINE
|
|
44 |
|
Calcium polycarbophil |
Approved |
Phase 2 |
|
126040-58-2 |
|
Synonyms:
Calcium polycarbophil
Polycarbophil calcium
|
|
|
45 |
|
Leuprolide |
Approved, Investigational |
Phase 2 |
|
53714-56-0 |
657181 |
Synonyms:
(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone
ABBOTT-43818
ABBOTT-43818 FREE BASE
ABBOTT-43818|Fensolvi® (leuprolide acetate injectable suspension)|Lupron®|TAP-144
Acetate, leuprolide
CKD-841
Enantone
Leuprolide
Leuprolide acetate
Leuprolide monoacetate
Leuprolide, (DL-leu)-isomer
Leuprolide, (L-leu)-isomer
Leuprorelin
|
Leuprorelin acetate
Leuprorelina
Leuproreline
Leuprorelinum
L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide
Lupron
Monoacetate, leuprolide
NSC-377526
PGlu-his-TRP-ser-tyr-D-leu-leu-arg-pro-NHC2H5
PGlu-his-TRP-ser-tyr-D-leu-leu-arg-pro-nhet
TAP 144
TAP-144
TAP-144 FREE BASE
|
|
46 |
|
Avelumab |
Approved, Investigational |
Phase 2 |
|
1537032-82-8 |
|
Synonyms:
AVELUMAB
BAVENCIO
MSB0010682
|
|
|
47 |
|
Estradiol |
Approved, Investigational, Vet_approved |
Phase 2 |
|
50-28-2 |
5757 |
Synonyms:
(+)-3,17B-ESTRADIOL
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17BETA)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
(17Î’)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
(1S,10R,11S,14S,15S)-15-METHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADECA-2,4,6-TRIENE-5,14-DIOL
(8R,9S,13S,14S,17S)-13-METHYL-6,7,8,9,11,12,14,15,16,17-DECAHYDROCYCLOPENTA[A]PHENANTHRENE-3,17-DIOL
[<sup>3</sup>H]-estradiol|[<sup>3</sup>H]-estrogen|[<sup>3</sup>H]E2|[<sup>3</sup>H]estradiol
13B-METHYL-1,3,5(10)-GONATRIENE-3,17B-OL
17 beta Estradiol
17 beta Oestradiol
17 beta-Estradiol
17 beta-Oestradiol
17b Oestradiol
17b-Estra-1,3,5(10)-triene-3,17-diol
17B-ESTRADIOL
17BETA OESTRADIOL
17BETA-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
17BETA-ESTRADIOL
17BETA-OESTRADIOL
17B-OESTRADIOL
17Î’ oestradiol
17Î’-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
17β-estradiol
17Î’-OESTRADIOL
3,17B-DIHYDROXYESTRA-1,3,5(10)-TRIENE
3,17B-ESTRADIOL
3,17-EPIDIHYDROXYESTRATRIENE
ADGYN ESTRO
AERODIOL
AGOFOLLIN
ALFATRADIOL
ALORA
ALTRAD
AMNESTROGEN
AQUADIOL
AQUAGEN
BARDIOL
BEDOL
B-ESTRADIOL
BETA-ESTRADIOL
CIS-ESTRADIOL
CLIMADERM
CLIMARA
CLIMARA PRO
COMPUDOSE
CORPAGEN
Delestrogen
DELTA-ESTRADIOL
DELTA-OESTRADIOL
DEPO-ESTRADIOL
DERMESTRIL
DERMESTRIL 100
DERMESTRIL 25
DERMESTRIL 50
DERMESTRIL SEPTEM 25
DERMESTRIL SEPTEM 50
DERMESTRIL SEPTEM 75
DESTRADIOL
D-ESTRADIOL
DIHYDROFOLLICULAR HORMONE
DIHYDROFOLLICULIN
DIHYDROMENFORMON
DIHYDROTHEELIN
DIHYDRO-THEELIN
DIHYDROXYESTRIN
DIMENFORMON
DIOGYN
DIOGYNETS
DIVIGEL
D-OESTRADIOL
E2
E2|estrogen|oestrodiol|oestrogen
E-CYPIONATE
ELESTRIM
ELESTRIN
ELLESTE SOLO
ELLESTE SOLO MX 40
ELLESTE SOLO MX 80
ENCORE
EPIESTRIOL 50
ESCLIM
ESTRA-1,3,5(10)-TRIENE-3,17B-DIOL
ESTRACE
ESTRADERM
ESTRADERM MX 100
ESTRADERM MX 25
ESTRADERM MX 50
ESTRADERM MX 75
ESTRADERM TTS
ESTRADERM TTS 100
ESTRADERM TTS 25
ESTRADERM TTS 50
ESTRADIOL
Estradiol 17 alpha
Estradiol 17 beta
Estradiol 17beta
Estradiol anhydrous
ESTRADIOL HEMIHYDRATE
Estradiol hemihydrate, (17 alpha)-isomer
Estradiol monohydrate
Estradiol orion brand
Estradiol valerate
Estradiol valeriante
|
Estradiol, (-)-isomer
Estradiol, (+-)-isomer
Estradiol, (16 alpha,17 alpha)-isomer
Estradiol, (16 alpha,17 beta)-isomer
Estradiol, (17-alpha)-isomer
Estradiol, (8 alpha,17 beta)-(+-)-isomer
Estradiol, (8 alpha,17 beta)-isomer
Estradiol, (9 beta,17 alpha)-isomer
Estradiol, (9 beta,17 beta)-isomer
Estradiol, monosodium salt
Estradiol, sodium salt
Estradiol-17 alpha
Estradiol-17 beta
Estradiol-17b
ESTRADIOL-17BETA
ESTRADIOL-17-BETA
Estradiol-17β
ESTRADIOLUM
ESTRADOT
ESTRALDINE
ESTRASORB
ESTRING
ESTRING VAGINAL RING
ESTROCLIM
ESTROCLIM 50
ESTROGEL
ESTROGEL HBF
ESTROGEN
ESTROVITE
EVAMIST
EVOREL
EVOREL 100
EVOREL 25
EVOREL 50
EVOREL 75
FEMATRIX 40
FEMATRIX 80
FEMESTRAL
FEMOGEN
FEMPATCH
FEMSEVEN 100
FEMSEVEN 50
FEMSEVEN 75
FOLLICYCLIN
GELESTRA
GINOSEDOL
GVNODIOL
GYNERGON
GYNODIOL
GYNOESTRYL
GYNOGEN
IMVEXXY
INNOFEM
LAMDIOL
MACRODIOL
MENOREST
MENOREST 37.5
MENOREST 50
MENOREST 75
MENORING 50
MENOSTAR
MINIVELLE
NORDICOL
Novartis pharmaceuticals brand OF estradiol
NSC-20293
NSC-9895
OESCLIM
OESTERGON
OESTRA-1,3,5(10)-TRIENE-3,17B-DIOL
OESTRADIOL
OESTRODIOL
OESTROGEL
OESTROGEN
OESTROGLANDOL
Orion brand OF estradiol
OVAHORMON
OVASTEROL
OVASTEVOL
OVOCYCLIN
OVOCYLIN
PERLATANOL
PRIMOFOL
PROFOLIOL
PROFOLIOL B
PROGYNON
Progynon depot
PROGYNON DH
Progynon-depot
Progynova
PROGYNOVA TS
SANDRENA
SANDRENA 1
SYNDIOL
SYSTEN
VAGIFEM
VAGIFEM 18
VAGIFEM 8
VIVELLE
VIVELLE-DOT
WC3011
WC-3011
ZUMENON
Î’-estradiol
|
|
48 |
|
Polyestradiol phosphate |
Approved |
Phase 2 |
|
28014-46-2 |
|
Synonyms:
(17-beta)-Estra-1,3,5(10)-triene-3,17-diol polymer with phosphoric acid
ESTRADIOL PHOSPHATE
Estradiol phosphate polymer
ESTRADURIN
Fosfato de poliestradiol
LEO-114
Oestradiol phosphate polymer
|
Phosphate de polyestradiol
Poly(estradiol phosphate)
POLYEST PHOS
POLYESTRADIOL PHOS PHOSPHATE
POLYESTRADIOL PHOSPHATE
Polyestradioli phosphas
|
|
49 |
|
Decitabine |
Approved, Investigational |
Phase 2 |
|
2353-33-5 |
451668 |
Synonyms:
2' Deoxy 5 azacytidine
2'-Deoxy-5-azacytidine
4-Amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
5 Aza 2' deoxycytidine
5 Azadeoxycytidine
5 Deoxyazacytidine
5-Aza-2'-deoxycytidine
5AzadC
5-AzadC
5-Azadeoxycytidine
|
5-Deoxyazacytidine
Azadc
AzadC compound
Compound, azadc
DAC
Dacogen
Decitabina
Decitabine
Decitabine mesylate
Dezocitidine
Mesylate, decitabine
NSC-127716
|
|
50 |
|
Atezolizumab |
Approved, Investigational |
Phase 2 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
Interventional clinical trials:
(show top 50)
(show all 89)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy for Postmenopausal Estrogen Receptor-positive Breast Cancer: a Prospective Randomized Controlled Double-blind Phase IV Trial |
Not yet recruiting |
NCT04137640 |
Phase 4 |
palbociclib combined with letrozole;epirubicin combined with cyclophosphamide and sequential docetaxel |
2 |
A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer |
Completed |
NCT00265759 |
Phase 3 |
anastrozole;exemestane;letrozole |
3 |
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study |
Active, not recruiting |
NCT01953588 |
Phase 3 |
fulvestrant;anastrozole |
4 |
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer |
Active, not recruiting |
NCT00066690 |
Phase 3 |
Exemestane;Tamoxifen;Triptorelin |
5 |
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
Active, not recruiting |
NCT02947685 |
Phase 3 |
palbociclib;trastuzumab;pertuzumab;letrozole;Anastrozole;Exemestane;Fulvestrant |
6 |
Randomized Phase II/III Study of Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic Estrogen Receptor Positive Breast Cancer |
Terminated |
NCT00684216 |
Phase 2, Phase 3 |
capecitabine;hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole) |
7 |
Letrozole With or Without Metronomic Capecitabine in First Line Treatment of Patients With ER-positive HER2 Negative Advanced Breast Cancer: A Randomized Phase II Study. |
Unknown status |
NCT04571437 |
Phase 2 |
Capecitabine;Letrozole 2.5mg |
8 |
A Randomized Phase II Study of Fulvestrant in Combination With the Dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant Alone in Estrogen Receptor-positive Advanced or Metastatic Breast Cancer |
Unknown status |
NCT02216786 |
Phase 2 |
AZD2014;Everolimus;Fulvestrant |
9 |
Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Post-menopausal, Estrogen Receptor Positive, Breast Cancer Patients |
Unknown status |
NCT00954135 |
Phase 2 |
letrozolo+cyclophosphamide;letrozolo+sorafenib+cyclophosphamide |
10 |
Single Arm Phase 2 Study of Metformin and Simvastatin in Addition to Fulvestrant in Metastatic Estrogen Receptor Positive Breast Cancer |
Unknown status |
NCT03192293 |
Phase 2 |
Metformin/Simvastatin/Fulvestrant |
11 |
Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy. |
Completed |
NCT02015559 |
Phase 2 |
mucoadhesive oral wound rinse |
12 |
Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer |
Completed |
NCT02988986 |
Phase 2 |
TAK-228;Tamoxifen |
13 |
A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor |
Completed |
NCT00676663 |
Phase 2 |
entinostat;exemestane;Placebo |
14 |
Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin + Daily Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Abraxaneâ„¢ for 12 Weeks With Concurrent Herceptin for Subjects With HER-2/Neu Positive Disease, Phase II |
Completed |
NCT00407888 |
Phase 2 |
doxorubicin hydrochloride;cyclophosphamide;paclitaxel albumin-stabilized nanoparticle formulation |
15 |
A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study |
Completed |
NCT00194779 |
Phase 2 |
doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole |
16 |
A Phase 2 Study of [18F] Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer |
Completed |
NCT00602043 |
Phase 2 |
|
17 |
Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast |
Completed |
NCT00952731 |
Phase 2 |
oral placebo;afimoxifene;tamoxifen citrate;placebo gel |
18 |
A Phase II Trial of Tipifarnib (R115777, Zarnestraâ„¢) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Hormone Receptor-Positive Breast Cancer |
Completed |
NCT00082810 |
Phase 2 |
fulvestrant;tipifarnib |
19 |
A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) Plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer |
Completed |
NCT00057941 |
Phase 2 |
anastrozole;gefitinib;fulvestrant |
20 |
A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF |
Completed |
NCT00003199 |
Phase 2 |
tamoxifen citrate;busulfan;thiotepa;melphalan |
21 |
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer |
Completed |
NCT01037790 |
Phase 2 |
PD-0332991 |
22 |
A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial |
Completed |
NCT01194440 |
Phase 2 |
letrozole;zoledronic acid |
23 |
A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI) |
Completed |
NCT00767520 |
Phase 2 |
Exemestane + Dasatinib;Exemestane + Placebo |
24 |
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients |
Completed |
NCT01605396 |
Phase 2 |
Ridaforolimus;Dalotuzumab;Exemestane |
25 |
A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg With Fulvestrant (FASLODEX®) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0). |
Completed |
NCT00093002 |
Phase 2 |
Fulvestrant |
26 |
A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients |
Completed |
NCT01234857 |
Phase 2 |
ridaforolimus + dalotuzumab;exemestane;ridaforolimus;dalotuzumab |
27 |
Phase II Open Label Study of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic, Estrogen Receptor Positive Breast Cancer, After Failure of Tamoxifen and/or Anastrozole and/or Letrozole and/or Fulvestrant and/or Exemestane |
Completed |
NCT01231659 |
Phase 2 |
Everolimus;Letrozole |
28 |
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy |
Recruiting |
NCT01984138 |
Phase 2 |
ESTRING;Replens |
29 |
A Randomized Phase 2 Non-inferiority Trial of (Z)-Endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment in Premenopausal Women With ER+/HER2- Breast Cancer |
Recruiting |
NCT05607004 |
Phase 2 |
Z-endoxifen;exemestane;goserelin |
30 |
A Phase 2 Study of VLS-101 in Patients With Solid Tumors |
Recruiting |
NCT04504916 |
Phase 2 |
Zilovertamab vedotin |
31 |
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer |
Recruiting |
NCT05076695 |
Phase 2 |
Palbociclib;trastuzumab;pyrotinib;fulvestrant |
32 |
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition |
Recruiting |
NCT04965688 |
Phase 2 |
Drug determined by treating oncologist based on recommendation from systems biology analysis. |
33 |
A Pilot Study of IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated With neoADjuvant Avelumab, Palbociclib, and Endocrine Therapy: The ImmunoADAPT Study |
Recruiting |
NCT03573648 |
Phase 2 |
Avelumab;Endocrine therapy;Palbociclib |
34 |
A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016 |
Active, not recruiting |
NCT02668666 |
Phase 2 |
Palbociclib;Tamoxifen |
35 |
A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor |
Active, not recruiting |
NCT01992952 |
Phase 1, Phase 2 |
AZD5363;Placebo;Fulvestrant |
36 |
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy |
Active, not recruiting |
NCT02957968 |
Phase 2 |
Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab |
37 |
A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer |
Active, not recruiting |
NCT03250676 |
Phase 1, Phase 2 |
H3B-6545 |
38 |
[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo ER in Endocrine Refractory Metastatic Breast Cancer |
Active, not recruiting |
NCT02409316 |
Phase 2 |
[18F]FES |
39 |
A Phase II Study Investigating Preoperative Combination Strategies for Immunotherapy in Patients With Untreated, Operable ER+, HER2-negative Primary Breast Cancer |
Active, not recruiting |
NCT03395899 |
Phase 2 |
Atezolizumab;Cobimetinib;Ipatasertib;Bevacizumab |
40 |
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer |
Active, not recruiting |
NCT03633331 |
Phase 2 |
Palbociclib;Letrozole;Fulvestrant |
41 |
PRe-operative ESTradiOl Window of Opportunity Study in Post-Menopausal Women With Newly Diagnosed ER Positive Breast Cancer |
Active, not recruiting |
NCT02238808 |
Phase 2 |
Estradiol |
42 |
A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer |
Not yet recruiting |
NCT05020860 |
Phase 2 |
Paclitaxel;Carboplatin;Trastuzumab;Pertuzumab;Doxorubicin;Cyclophosphamide |
43 |
A Pilot Study of 68-Ga-RM2 PET/MRI in the Evaluation of Patients With Estrogen Receptor-Positive Breast Cancer |
Suspended |
NCT03831711 |
Phase 1, Phase 2 |
Gallium Ga 68-labeled GRPR Antagonist BAY86-7548 |
44 |
Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer |
Suspended |
NCT02778685 |
Phase 2 |
Fulvestrant;Letrozole;Palbociclib |
45 |
A Phase II Non Randomized Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) |
Terminated |
NCT02000375 |
Phase 2 |
DHEA |
46 |
Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer |
Terminated |
NCT02269670 |
Phase 2 |
everolimus;anastrozole;letrozole;tamoxifen citrate;fulvestrant;megestrol acetate |
47 |
Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma |
Terminated |
NCT02273752 |
Phase 2 |
Everolimus |
48 |
Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study |
Terminated |
NCT00194792 |
Phase 2 |
exemestane;triptorelin pamoate;capecitabine;methotrexate;vinorelbine tartrate;paclitaxel |
49 |
A Multisite International Collaborative Phase 2 Study of Neoadjuvant Goserelin and a Non-steroidal Aromatase Inhibitor for Premenopausal Women With Estrogen Receptor Positive HER2 Negative Clinical Stage 2 and 3 Breast Cancer |
Terminated |
NCT01368263 |
Phase 2 |
goserelin acetate;letrozole;anastrozole;chemotherapy |
50 |
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer |
Terminated |
NCT01394211 |
Phase 2 |
anastrozole;pazopanib hydrochloride |
|